Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised,Double-blind,Placebo-controlled Study to Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride (SY-004) in Chinese Healthy Subjects

NCT03171623 is registered in ClinicalTrials.gov with Yabao Pharmaceutical Group as lead sponsor.

NCT NCT03171623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03171623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised,Double-blind,Placebo-controlled Study to Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride (SY-004) in Chinese Healthy Subjects
Lead sponsor
Yabao Pharmaceutical Group
Phase
Phase 1
Overall status
Completed
Start date
April 5, 2017
Completion date
January 9, 2018
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hyperglycaemia (diabetic)